TVB-2640
SB2640-CLIN-007
Phase 2 small_molecule completed
Quick answer
TVB-2640 for Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease is a Phase 2 program (small_molecule) at Sagimet Biosciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sagimet Biosciences
- Indication
- Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed